Inhibition of an in vitro CD4+ T cells alloresponse using altered peptide ligands

Journal of Immunology

Volumn 160, Issue 7, 1998, Pages 3244-3250

  Daniel, Claude ^a   Grakoui, Arash ^a   Allen, Paul M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; COMPLEMENTARY DNA; CYTOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; HYBRIDOMA; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIGEN-PRESENTING CELLS; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES; HEMOGLOBINS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HYBRIDOMAS; IMMUNOSUPPRESSIVE AGENTS; INTERPHASE; LIGANDS; MICE; MICE, INBRED A; MICE, INBRED AKR; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, INBRED DBA; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; TH1 CELLS; TH2 CELLS; TUMOR CELLS, CULTURED;

EID: 0032055548     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Opelz, G. 1992. Collaborative transplant study: 10-year report. Transplant. Proc. 24:2342.
2. Kurki, P. T. 1992. Safety aspects of the long term cyclosporin A therapy. Scand. J. Rheumatol. 21:35.
3. Ryffel, B. 1992. The carcinogenicity of cyclosporin. Toxicology 73:1.
4. Opelz, G. 1995. Influence of treatment with cyclosporin, azathioprine and steroids on chronic allograft failure. Kidney Int. 48. S52:89.
5. Sketris, I., R. Yatscoff, P. Keown, D. M. Canafax, M. R. First, D. W. Holt, T. J. Schroeder, and M. Wright. 1995. Optimizing the use of cyclosporin in renal transplantation. Clin. Biochem. 28:195.
6. Krensky, A. M., and C. Clayberger. 1994. The induction of tolerance to alloantigens using HLA-based synthetic peptides. Curr. Opin. Immunol. 6:791.
7. Larsen, C. P., E. T. Elwood, D. Z. Alezander, S. C. Ritchie, R. Hendrix, C. Tucker-Burden, H. R. Cho, A. Aruffo, D. Hollenbaugh, P. S. Linsley, K. J. Winn, and T. C. Pearson. 1996. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381:434.
8. Kersh, G. J., and P. M. Allen. 1996. Essential flexibility in the T-cell recognition of antigen. Nature 222:495.
9. Evavold, B. D., and P. M. Allen. 1991. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 252:1308.
10. Pfeiffer, C., J. Stein, S. Southwood, H. Ketelaar, A. Sette, and K. Bottomly. 1995. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J. Exp. Med. 181:1569.
11. Windhagen, A., C. Scholz, P. Höllsberg, H. Fukaura, A. Sette, and D. A. Hafler. 1995. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 2:373.
12. Sloan-Lancaster, J., B. D. Evavold, and P. M. Allen. 1993. Induction of T-cell anergy by altered T-cell-receplor ligand on live antigen-presenting cells. Nature 363:156.
13. Evavold, B. D., J. Sloan-Lancaster, and P. M. Allen. 1994. Antagonism of superantigen-stimulated helper T-cell clones and hybridomas by altered peptide ligand. Proc. Natl. Acad. Sci. USA 91:2300.
14. De Magistris, M. T., J. Alexander, M. Coggeshall, A. Altman, F. C. A. Gaeta, H. M. Grey, and A. Sette. 1992. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 68:625.
15. Jameson, S. C., F. R. Carbone, and M. J. Bevan. 1993. Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells. J. Exp. Med. 177:1541.
16. Ruppert, J., A. Franco, J. Alexander, K. Snoke, G. Y. Ishioka, D. M. Page, S. M. Hedrick, L. Adorini, H. M. Grey, and A. Sette. 1995. MHC blocking peptides and T-cell receptor antagonists: novel paths to selective immunosuppression. Chem. Immunol. 60:61.
17. Smilek, D. E., D. C. Wraith, S. Hodgkinson, S. Dwivedy, L. Steinman, and H. O. McDevitt. 1991. A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 88:9633.
18. Karin, N., D. J. Mitchell, S. Brocke, N. Ling, and L. Steinman. 1994. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon γ and tumor necrosis factor α production. J. Exp. Med. 180:2227.
19. Lorenz, R. G., and P. M. Allen. 1988. Direct evidence for functional self protein/ Ia-molecule complexes in vivo. Proc. Natl. Acad. Sci. USA 85:5220.
20. Evavold, B. D., S. G. Williams, B. L. Hsu, S. Buus, and P. M. Allen. 1992. Complete dissection of the Hb(64-76) determinant using Th1, Th2 clones, and T cell hybridomas. J. Immunol. 148:347.
21. Fremont, D. H., W. A. Hendrickson, P. Marrack, and J. Kappler. 1996. Structures of an MHC class II molecule with covalently bound single peptides. Science 272:1001.
22. Kersh, G. J., and P. M. Allen. 1996. Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands. J. Exp. Med. 184:1259.
23. Stimpfling, J. H., and A. E. Reichert. 1970. Strain C57BL/10ScSn and its congenic resistant sublines. Transplant. Proc. 1:39.
24. Evavold, B. D., J. Sloan-Lancaster, B. L. Hsu, and P. M. Allen. 1993. Separation of T helper 1 clone cytolysis from proliferation and lymphokine production using analog peptides. J. Immunol. 150:3131.
25. + normal B cells. Immunol. Rev. 93:35.
26. Springer, T. A. 1980. Cell-surface differentiation in the mouse. In Monoclonal Antibodies. R. H. Kennett, T. J. McKearn, and K. B. Bechtol, eds. Plenum Press, New York, pp. 185-217.
27. Szabo, S. J., N. G. Jacobson, A. S. Dighe, U. Gubler, and K. M. Murphy. 1995. Developmental commitment to the TH2 lineage by extinction of IL-12 signaling. Immunity 2:665.
28. Vidal, K., B. L. Hsu, C. B. Williams, and P. M. Allen. 1996. Endogenous altered peptide ligands can affect peripheral T cell responses. J. Exp. Med 183:1311.
29. p haplotypes. Immunogenetics 44:231.
30. Strom, T. B., P. Roy-Chaudhury, R. Manfro, X. X. Zheng, P. W. Nickerson, K. Wood, and A. Bushell. 1996. The Th1/Th2 paradigm and the allograft response. Curr. Opin. Immunol. 8::688.
31. Racioppi, L., F. Ronchese, L. A. Matis, and R. N. Germain. 1993. Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling. J. Exp. Med. 177:1047.
32. Jones, P. P., D. B. Murphy, and H. O. McDevitt. 1981. Variable synthesis and expression of E alpha and Ae (E beta) Ia polypeptide chains in mice of different H-2 haplotypes. Immunogenetics 12:321.
33. Sherman, L. A, and S. Chattopadhyay. 1993. The molecular basis of allorecognition. Annu. Rev. Immunol. 11:385.
34. Matzinger, P., and M. J. Bevan. 1977. Why do so many lymphocytes respond to major histocompatibility antigens? Cell. Immunol. 29:1.
35. Smith, P. A., A. Brunmark, M. R. Jackson, and T. A. Potter. 1997. Peptide-independent recognition by alloreactive cytotoxic T lymphocytes (CTL). J. Exp. Med. 185:1023.
36. Cotner, T., E. Mellins, A. H. Johnson, and D. Pious. 1991. Mutations affecting antigen processing impair class II-restricted allorecognition. J. Immunol. 146: 414.
37. Rötzschke, O., K. Falk, S. Faath, and H.-G. Rammensee. 1991. On the nature of peptides involved in T cell alloreactivity. J. Exp. Med. 174:1059.
38. Kuzushima, K., R. Sun, G. M. Van Bleek, Z. Vegh, and S. G. Nathenson. 1995. The role of self peptides in the allogeneic cross-reactivity of CTLs. J. Immunol. 155:594.
39. + cytotoxic T lymphocytes in association with a class I MHC protein. Cell 69:989.
40. Panina-Bordignon, P., G. Corradin, E. Roosnek, A. Sette, and A. Lanzavecchia. 1991. Recognition by class II alloreactive T cells of processed determinants from human serum proteins. Science 252:1548.
41. + T cell recognition of class II MHC molecules. J. Immunol. 154:5153.
42. Brock, R., K.-H. Wiesmüller, G. Jung, and P. Walden. 1996. Molecular basis for the recognition of two structurally different major histocompatibility complex/ peptide complexes by a single T-cell receptor. Proc. Natl. Acad. Sci. USA 93:13108.
43. Sykulev, Y., A. Brunmark, T. J. Tsomides, S. Kageyama, M. Jackson, P. A. Peterson, and H. N. Eisen. 1997. High-affinity reactions between antigen-specific T-cell receptors and peptides associated with allogeneic and syngeneic major histocompatibility complex class I proteins. Proc. Natl. Acad. Sci. USA 91:11487.
44. + T cells in response to antagonist ligands. J. Exp. Med. 184:149.
45. La Face, D. M., C. Couture, K. Anderson, G. Shih, J. Alexander, A. Sette, T. Mustelin, A. Altman, and H. M. Grey. 1997. Differential T cell signaling induced by antagonist peptide-MHC complexes and the associated phenotypic responses. J. Immunol. 158:2057.
46. Madrenas, J., R. L. Wange, J. L. Wang, N. Isakov, L. E. Samelson, and R. N. Germain. 1995. ζ Phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists. Science 267:515.
47. Sloan-Lancaster, J., A. S. Shaw, J. B. Rothbard, and P. M. Allen. 1994. Partial T cell signaling: altered phospho-ζ and lack of Zap 70 recruitment in APL-induced T cell anergy. Cell 79:913.
48. Ruppert, J., J. Alexander, K. Snoke, M. Coggeshall, E. Herbert, D. McKenzie, H. M. Grey, and A. Sette. 1993. Effect of T-cell receptor antagonism on interaction between T cells and antigen-presenting cells and on T-cell signaling events. Proc. Natl. Acad. Sci. USA 90:2671.
49. Wauben, M. H. M., C. J. P. Boog, R. van der Zee, I. Joosten, A. Schlief, and W. van Eden. 1992. Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone. J. Exp. Med. 176:667.
50. Kuchroo, V. K., J. M. Greer, D. Kaul, G. Ishioka, A. Franco, A. Sette, R. Sobel, and M. B. Lees. 1994. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J. Immunol. 153:3326.
51. Franco, A., S. Southwood, T. Arrhenius, V. K. Kuchroo, H. M. Grey A. Sette, and G. Y. Ishioka. 1994. T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis. Eur. J. Immunol. 24:940.
52. Nicholson, L. B., J. M. Greer, R. A. Sobel, M. B. Lees, and V. K. Kuchroo. 1995. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 3:397.
53. Brocke, S., K. Gijbels, M. Allegretta, I. Ferber, C. Piercy, T. Blankenstein, R. Martin, U. Utz, N. Karin, D. Mitchell, T. Veromaa, A. Waisman, A. Gaur, P. Conlon, N. Ling, P. J. Fairchild, D. C. Wraith, A. O'Garra, C. G. Fathman, and L. Steinman. 1996. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 379:343.
54. Dittel, B. N., D. B. Sant'Angelo, and C. A. Janeway, Jr. 1997. Peptide antagonists inhibit proliferation and the production of IL-4 and/or IFN-γ in T helper 1, T helper 2, and T helper 0 clones bearing the same TCR. J. Immunol. 158:4065.